Ankur Raj Sangoi, MD
Pathology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 21 years
- Saint Louis University School of Medicine, 2005
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Sangoi’s office at (650) 723-4000 to ask if they take your plan before you enroll.
California Medical Board record
Licence A96558 · Current
Licensed to practise in California · since 2006 · expires 2027-11-30 · Saint Louis University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Pathology - Pathology – Anatomic/Pathology- Clinical
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$140,644
Medicare paid this office $140,644 for 911 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 204 | $33,275 | $162 |
| Pathology examination of tissue using a microscope, moderately high complexity | 220 | $26,206 | $74 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 321 | $23,438 | $72 |
| Special stained specimen slides to examine tissue, each additional procedure | 148 | $12,634 | $25 |
| Pathology examination of tissue using a microscope, high complexity | 56 | $9,872 | $133 |
See all 15 services
| Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 204 | $33,275 | $162 |
| Pathology examination of tissue using a microscope, moderately high complexity | 220 | $26,206 | $74 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 321 | $23,438 | $72 |
| Special stained specimen slides to examine tissue, each additional procedure | 148 | $12,634 | $25 |
| Pathology examination of tissue using a microscope, high complexity | 56 | $9,872 | $133 |
| Pathology examination of tissue using a microscope, intermediate complexity | 156 | $8,181 | $34 |
| Special stained specimen slides to examine tissue, each multiplex procedure | 94 | $7,475 | $35 |
| Special stained specimen slides to examine tissue, initial procedure | 189 | $7,417 | $32 |
| Pathology examination of specimen during surgery, first tissue block | 45 | $4,803 | $57 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 34 | $2,747 | $81 |
| Microscopic genetic analysis of tumor, manual | 30 | $1,253 | $38 |
| Genetic sequencing localization, initial procedure | 19 | $823 | $39 |
| Special stained specimen slides to examine tissue including interpretation and report | 38 | $534 | $11 |
| Pathology examination of tissue using a microscope, moderately low complexity | 37 | $425 | $10 |
| Pathology examination of tissue using a microscope | 13 | $93 | $6 |
Who their Medicare patients are
911 Original Medicare patients in 2024. Average age 74 · Under 65 3% · 85 and older 7% · Women 16% · Also on Medicaid 15% · Health risk score 1.23. At or below the middle of the specialty; the typical pathology clinician is at 1.55.
Conditions among them: Cancer 72% · High blood pressure 70% · Coronary heart disease 29% · Chronic kidney disease 29% · Diabetes 26% · Atrial fibrillation 18% · Heart failure 12% · Depression 12% · COPD 9% · Stroke 7% · Dementia 4%.
The office billed $1,704,757, Medicare allowed $178,050 and paid $140,644; for 2,489 services of 26 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 911 | 2,489 | 74 | 1.23 | $1,704,757 | $140,644 |
| 2023 | 1,072 | 2,805 | 75 | 1.35 | $1,132,980 | $134,975 |
| 2022 | 1,278 | 3,950 | 77 | 1.22 | $625,878 | $157,046 |
| 2021 | 1,234 | 4,234 | 75 | 1.20 | $705,800 | $175,883 |
| 2020 | 1,118 | 3,517 | 75 | 1.16 | $619,739 | $156,890 |
| 2019 | 1,307 | 4,444 | 75 | 1.21 | $740,284 | $189,910 |
| 2018 | 1,122 | 4,050 | 75 | 1.18 | $661,752 | $164,741 |
| 2017 | 1,064 | 3,957 | 74 | 1.28 | $606,052 | $148,691 |
| 2016 | 900 | 3,389 | 74 | 1.20 | $529,175 | $127,718 |
| 2015 | 913 | 3,110 | 74 | 1.17 | $483,263 | $112,147 |
| 2014 | 877 | 3,536 | 74 | 1.15 | $563,598 | $116,676 |
| 2013 | 767 | 2,715 | 74 | 1.15 | $435,957 | $101,351 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 19 services
| Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 169 | $27,602 | $162 |
| Pathology examination of tissue using a microscope, moderately high complexity | 212 | $26,127 | $76 |
| Surgical pathology consultation and report on referred slides prepared elsewhere | 226 | $17,665 | $76 |
| Pathology examination of tissue using a microscope, intermediate complexity | 246 | $13,503 | $33 |
| Special stained specimen slides to examine tissue, each additional procedure | 113 | $12,819 | $26 |
| Pathology examination of tissue using a microscope, high complexity | 53 | $7,917 | $132 |
| Special stained specimen slides to examine tissue, each multiplex procedure | 103 | $6,910 | $35 |
| Special stained specimen slides to examine tissue, initial procedure | 161 | $5,865 | $32 |
| Protein measurement, serum | 201 | $5,102 | $16 |
| Pathology examination of specimen during surgery, first tissue block | 34 | $3,339 | $58 |
| Surgical pathology consultation and report on referred material requiring preparation of slides | 25 | $2,092 | $80 |
| Microscopic genetic analysis of tumor, manual | 25 | $1,189 | $38 |
| Immunologic analysis technique on serum (immunofixation) | 47 | $815 | $16 |
| Protein measurement, body fluid | 46 | $750 | $16 |
| Genetic sequencing localization, initial procedure | 13 | $555 | $40 |
| Cell examination of specimen, selective cellular enhancement technique | 18 | $481 | $25 |
| Pathology examination of tissue using a microscope, moderately low complexity | 25 | $239 | $10 |
| Immunologic analysis technique on body fluid, other fluids with concentration | 13 | $200 | $15 |
| Pathology examination of tissue using a microscope, limited examination | 42 | $171 | $4 |
2022: 21 services
| Pathology examination of tissue using a microscope, intermediate complexity | 589 | $34,463 | $35 |
| Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 164 | $27,192 | $165 |
| Pathology examination of tissue using a microscope, moderately high complexity | 225 | $25,514 | $77 |
| Special stained specimen slides to examine tissue, each additional procedure | 157 | $16,935 | $26 |
| Special stained specimen slides to examine tissue, each multiplex procedure | 238 | $16,590 | $36 |
| Special stained specimen slides to examine tissue, initial procedure | 253 | $9,991 | $32 |
| Pathology examination of tissue using a microscope, high complexity | 34 | $5,026 | $136 |
| Protein measurement, serum | 162 | $3,953 | $17 |
| Cell examination of specimen, selective cellular enhancement technique | 113 | $3,226 | $25 |
| Pathology examination of specimen during surgery, first tissue block | 31 | $2,622 | $58 |
| Microscopic genetic analysis of tumor, manual | 25 | $2,323 | $39 |
| Special stained specimen slides to identify organisms including interpretation and report | 43 | $1,734 | $24 |
| Evaluation of fine needle aspirate with interpretation and report | 22 | $1,633 | $65 |
| Immunologic analysis technique on serum (immunofixation) | 32 | $747 | $17 |
| Examination of archival tissue for genetic analysis | 36 | $615 | $17 |
| Protein measurement, body fluid | 36 | $598 | $17 |
| Pathology examination of tissue using a microscope, limited examination | 132 | $584 | $4 |
| Pathology examination of tissue using a microscope, moderately low complexity | 53 | $570 | $10 |
| Preparation of tissue for examination by removing any calcium present | 23 | $266 | $12 |
| Special stained specimen slides to examine tissue including interpretation and report | 17 | $201 | $11 |
| Immunologic analysis technique on body fluid, other fluids with concentration | 11 | $183 | $17 |
2021: 18 services
| Pathology examination of tissue using a microscope, intermediate complexity | 756 | $45,320 | $35 |
| Pathology examination of tissue using a microscope, moderately high complexity | 243 | $28,394 | $79 |
| Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 138 | $23,482 | $169 |
| Special stained specimen slides to examine tissue, each additional procedure | 189 | $20,606 | $27 |
| Special stained specimen slides to examine tissue, each multiplex procedure | 247 | $17,586 | $36 |
| Special stained specimen slides to examine tissue, initial procedure | 332 | $13,117 | $33 |
| Pathology examination of tissue using a microscope, high complexity | 39 | $6,030 | $140 |
| Cell examination of specimen, selective cellular enhancement technique | 113 | $3,414 | $26 |
| Evaluation of fine needle aspirate with interpretation and report | 40 | $3,362 | $67 |
| Pathology examination of specimen during surgery, first tissue block | 29 | $3,341 | $60 |
| Microscopic genetic analysis of tumor, manual | 31 | $3,285 | $40 |
| Special stained specimen slides to identify organisms including interpretation and report | 49 | $1,956 | $25 |
| Pathology examination of tissue using a microscope, moderately low complexity | 64 | $724 | $10 |
| Examination of archival tissue for genetic analysis | 32 | $601 | $18 |
| Evaluation of fine needle aspirate | 15 | $549 | $34 |
| Pathology examination of tissue using a microscope, limited examination | 110 | $478 | $4 |
| Special stained specimen slides to examine tissue including interpretation and report | 23 | $332 | $11 |
| Preparation of tissue for examination by removing any calcium present | 19 | $228 | $11 |
2020: 17 services
| Pathology examination of tissue using a microscope, intermediate complexity | 684 | $43,666 | $35 |
| Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 171 | $29,769 | $174 |
| Pathology examination of tissue using a microscope, moderately high complexity | 194 | $21,681 | $81 |
| Special stained specimen slides to examine tissue, each multiplex procedure | 205 | $15,974 | $37 |
| Special stained specimen slides to examine tissue, each additional procedure | 142 | $13,229 | $28 |
| Special stained specimen slides to examine tissue, initial procedure | 250 | $10,568 | $34 |
| Pathology examination of tissue using a microscope, high complexity | 43 | $6,364 | $145 |
| Evaluation of fine needle aspirate with interpretation and report | 31 | $3,078 | $68 |
| Cell examination of specimen, selective cellular enhancement technique | 100 | $3,031 | $27 |
| Pathology examination of specimen during surgery, first tissue block | 23 | $2,053 | $62 |
| Special stained specimen slides to identify organisms including interpretation and report | 41 | $1,669 | $26 |
| Microscopic genetic analysis of tumor, manual | 14 | $1,416 | $42 |
| Pathology examination of tissue using a microscope, moderately low complexity | 61 | $687 | $11 |
| Special stained specimen slides to examine tissue including interpretation and report | 30 | $434 | $12 |
| Pathology examination of tissue using a microscope, limited examination | 87 | $392 | $4 |
| Examination of archival tissue for genetic analysis | 15 | $286 | $19 |
| Preparation of tissue for examination by removing any calcium present | 22 | $280 | $12 |
2019: 19 services
| Pathology examination of tissue using a microscope, intermediate complexity | 826 | $57,554 | $36 |
| Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 173 | $29,483 | $170 |
| Pathology examination of tissue using a microscope, moderately high complexity | 195 | $25,331 | $80 |
| Special stained specimen slides to examine tissue, each additional procedure | 178 | $19,286 | $28 |
| Special stained specimen slides to examine tissue, each multiplex procedure | 195 | $15,690 | $37 |
| Special stained specimen slides to examine tissue, initial procedure | 291 | $12,626 | $34 |
| Pathology examination of tissue using a microscope, high complexity | 51 | $7,824 | $142 |
| Evaluation of fine needle aspirate with interpretation and report | 48 | $4,366 | $68 |
| Pathology examination of specimen during surgery, first tissue block | 41 | $4,196 | $61 |
| Cell examination of specimen, selective cellular enhancement technique | 114 | $3,420 | $27 |
| Special stained specimen slides to identify organisms including interpretation and report | 47 | $1,735 | $26 |
| Microscopic genetic analysis of tumor, manual | 17 | $1,386 | $41 |
| Evaluation of fine needle aspirate | 27 | $1,155 | $35 |
| Pathology examination of tissue using a microscope, moderately low complexity | 68 | $794 | $11 |
| Pathology examination of tissue using a microscope, limited examination | 148 | $646 | $4 |
| Special stained specimen slides to examine tissue including interpretation and report | 32 | $483 | $11 |
| Examination of archival tissue for genetic analysis | 24 | $469 | $19 |
| Pathology examination of specimen during surgery | 12 | $410 | $34 |
| Preparation of tissue for examination by removing any calcium present | 16 | $226 | $12 |
2018: 20 services
| Pathology examination of tissue using a microscope, intermediate complexity | 729 | $56,359 | $35 |
| Pathology examination of tissue using a microscope, moderately high complexity | 197 | $26,077 | $80 |
| Special stained specimen slides to examine tissue, each additional procedure | 171 | $17,495 | $27 |
| Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 100 | $16,120 | $161 |
| Special stained specimen slides to examine tissue, each multiplex procedure | 149 | $11,622 | $37 |
| Special stained specimen slides to examine tissue, initial procedure | 268 | $11,552 | $34 |
| Pathology examination of tissue using a microscope, high complexity | 47 | $6,823 | $142 |
| Pathology examination of specimen during surgery, first tissue block | 37 | $3,039 | $61 |
| Evaluation of fine needle aspirate with interpretation and report | 26 | $2,825 | $66 |
| Microscopic genetic analysis of tumor, manual | 28 | $2,430 | $43 |
| Cell examination of specimen, selective cellular enhancement technique | 72 | $2,142 | $26 |
| Special stained specimen slides to identify organisms including interpretation and report | 53 | $2,119 | $25 |
| Pathology examination of tissue using a microscope, moderately low complexity | 60 | $695 | $11 |
| Evaluation of fine needle aspirate | 13 | $694 | $35 |
| Pathology examination of specimen during surgery | 16 | $549 | $34 |
| Pathology examination of specimen during surgery, each additional tissue block | 12 | $540 | $30 |
| Special stained specimen slides to examine tissue including interpretation and report | 36 | $444 | $11 |
| Pathology examination of tissue using a microscope, limited examination | 99 | $433 | $4 |
| Preparation of tissue for examination by removing any calcium present | 32 | $409 | $12 |
| Examination of archival tissue for genetic analysis | 15 | $282 | $19 |
2017: 23 services
| Pathology examination of tissue using a microscope, intermediate complexity | 706 | $48,518 | $35 |
| Pathology examination of tissue using a microscope, moderately high complexity | 162 | $19,511 | $80 |
| Special stained specimen slides to examine tissue, each additional procedure | 163 | $17,337 | $26 |
| Special stained specimen slides to examine tissue, initial procedure | 277 | $11,634 | $34 |
| Special stained specimen slides to examine tissue, each multiplex procedure | 118 | $10,636 | $37 |
| Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 50 | $8,584 | $168 |
| Microscopic genetic analysis of tumor, manual | 43 | $5,394 | $51 |
| Pathology examination of tissue using a microscope, high complexity | 33 | $5,107 | $142 |
| Evaluation of fine needle aspirate with interpretation and report | 45 | $4,119 | $68 |
| Pathology examination of specimen during surgery, first tissue block | 35 | $3,074 | $60 |
| Cell examination of specimen, selective cellular enhancement technique | 95 | $2,872 | $26 |
| Special stained specimen slides to identify organisms including interpretation and report | 63 | $2,187 | $26 |
| Evaluation of fine needle aspirate | 28 | $1,211 | $35 |
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 11 | $916 | $83 |
| Microscopic genetic analysis of tissue, computer-assisted technology, initial procedure, each multiplex procedure | 11 | $914 | $42 |
| Special stained specimen slides to examine tissue including interpretation and report | 56 | $880 | $11 |
| Pathology examination of specimen during surgery | 21 | $725 | $33 |
| Preparation of tissue for examination by removing any calcium present | 42 | $637 | $12 |
| Pathology examination of tissue using a microscope, moderately low complexity | 52 | $611 | $11 |
| Pathology examination of tissue using a microscope, limited examination | 122 | $568 | $4 |
| Genetic sequencing localization, initial procedure | 12 | $503 | $42 |
| Examination of archival tissue for genetic analysis | 20 | $367 | $18 |
| Pathology examination of tissue using a microscope | 11 | $74 | $7 |
2016: 21 services
| Pathology examination of tissue using a microscope, intermediate complexity | 601 | $42,810 | $35 |
| Pathology examination of tissue using a microscope, moderately high complexity | 123 | $14,910 | $79 |
| Special stained specimen slides to examine tissue, each additional procedure | 132 | $14,110 | $25 |
| Special stained specimen slides to examine tissue, initial procedure | 212 | $8,664 | $34 |
| Special stained specimen slides to examine tissue, each multiplex procedure | 85 | $7,232 | $37 |
| Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 47 | $6,707 | $143 |
| Pathology examination of tissue using a microscope, high complexity | 34 | $6,211 | $141 |
| Microscopic genetic analysis of tumor, manual | 44 | $5,335 | $50 |
| Evaluation of fine needle aspirate with interpretation and report | 35 | $4,042 | $67 |
| Pathology examination of specimen during surgery, first tissue block | 38 | $3,167 | $60 |
| Cell examination of specimen, selective cellular enhancement technique | 80 | $2,445 | $26 |
| Special stained specimen slides to identify organisms including interpretation and report | 52 | $1,952 | $26 |
| Flow cytometry technique for dna or cell analysis, 16 or more markers | 16 | $1,730 | $102 |
| Special stained specimen slides to examine tissue including interpretation and report | 49 | $831 | $11 |
| Pathology examination of specimen during surgery, each additional tissue block | 18 | $796 | $29 |
| Evaluation of fine needle aspirate | 21 | $794 | $35 |
| Preparation of tissue for examination by removing any calcium present | 54 | $767 | $12 |
| Pathology examination of tissue using a microscope, moderately low complexity | 63 | $702 | $10 |
| Bone marrow, smear interpretation | 12 | $547 | $46 |
| Pathology examination of specimen during surgery | 13 | $444 | $34 |
| Pathology examination of tissue using a microscope, limited examination | 100 | $432 | $4 |
2015: 20 services
| Pathology examination of tissue using a microscope, intermediate complexity | 573 | $39,571 | $34 |
| Pathology examination of tissue using a microscope, moderately high complexity | 119 | $17,406 | $79 |
| Special stained specimen slides to examine tissue, each additional procedure | 110 | $9,472 | $20 |
| Special stained specimen slides to examine tissue, initial procedure | 213 | $8,926 | $33 |
| Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | 45 | $7,600 | $169 |
| Pathology examination of tissue using a microscope, high complexity | 25 | $3,749 | $139 |
| Special stained specimen slides to examine tissue, each multiplex procedure | 54 | $3,653 | $37 |
| Microscopic genetic analysis of tumor, manual | 33 | $3,124 | $50 |
| Pathology examination of specimen during surgery, first tissue block | 37 | $2,513 | $58 |
| Cell examination of specimen, selective cellular enhancement technique | 82 | $2,464 | $26 |
| Evaluation of fine needle aspirate with interpretation and report | 24 | $2,376 | $66 |
| Special stained specimen slides to identify organisms including interpretation and report | 42 | $1,748 | $25 |
| Pathology examination of tissue using a microscope, moderately low complexity | 73 | $831 | $11 |
| Pathology cytologic examination of specimen during surgery, initial site | 14 | $831 | $59 |
| Special stained specimen slides to examine tissue including interpretation and report | 48 | $798 | $11 |
| Evaluation of fine needle aspirate | 13 | $715 | $34 |
| Pathology examination of tissue using a microscope, limited examination | 124 | $584 | $4 |
| Preparation of tissue for examination by removing any calcium present | 44 | $557 | $12 |
| Pathology examination of specimen during surgery, each additional tissue block | 12 | $495 | $29 |
| Pathology examination of specimen during surgery | 11 | $367 | $33 |
2014: 19 services
| Pathology examination of tissue using a microscope, intermediate complexity | 614 | $45,525 | $34 |
| Pathology examination of tissue using a microscope, moderately high complexity | 125 | $20,907 | $76 |
| Immunohistochemistry or immunocytochemistry, per specimen; first single or multiplex antibody stain | 273 | $9,921 | $27 |
| Immunohistochemistry or immunocytochemistry, per specimen; each additional single or multiplex antibody stain (list separately in addition to code for primary procedure) | 164 | $7,013 | $11 |
| Pathology examination of tissue using a microscope, high complexity | 33 | $4,706 | $134 |
| Microscopic genetic analysis of tumor, manual | 40 | $4,109 | $48 |
| Pathology examination of specimen during surgery, first tissue block | 52 | $4,108 | $57 |
| Evaluation of fine needle aspirate with interpretation and report | 41 | $3,750 | $65 |
| Cell examination of specimen, selective cellular enhancement technique | 100 | $2,851 | $25 |
| Special stained specimen slides to identify organisms including interpretation and report | 54 | $2,265 | $25 |
| Evaluation of fine needle aspirate | 27 | $1,181 | $33 |
| Pathology examination of tissue using a microscope, moderately low complexity | 74 | $837 | $10 |
| Pathology examination of specimen during surgery, each additional tissue block | 25 | $819 | $28 |
| Pathology examination of specimen during surgery | 24 | $782 | $33 |
| Special stained specimen slides to examine tissue including interpretation and report | 42 | $595 | $11 |
| Bone marrow, smear interpretation | 12 | $523 | $44 |
| Preparation of tissue for examination by removing any calcium present | 41 | $493 | $11 |
| Pathology examination of tissue using a microscope, limited examination | 81 | $342 | $4 |
| Examination of archival tissue for genetic analysis | 12 | $220 | $17 |
2013: 15 services
| Pathology examination of tissue using a microscope, intermediate complexity | 551 | $38,695 | $33 |
| Special stained specimen slides to examine tissue, initial procedure | 198 | $26,635 | $38 |
| Pathology examination of tissue using a microscope, moderately high complexity | 90 | $12,968 | $75 |
| Microscopic genetic analysis of tumor, manual | 36 | $4,408 | $47 |
| Pathology examination of tissue using a microscope, high complexity | 26 | $3,554 | $132 |
| Cell examination of specimen, selective cellular enhancement technique | 56 | $3,506 | $52 |
| Pathology examination of specimen during surgery, first tissue block | 32 | $2,526 | $56 |
| Special stained specimen slides to identify organisms including interpretation and report | 39 | $1,541 | $24 |
| Evaluation of fine needle aspirate with interpretation and report | 17 | $1,275 | $61 |
| Pathology examination of tissue using a microscope, moderately low complexity | 61 | $645 | $10 |
| Special stained specimen slides to examine tissue including interpretation and report | 30 | $479 | $11 |
| Pathology examination of specimen during surgery | 14 | $449 | $32 |
| Pathology examination of specimen during surgery, each additional tissue block | 11 | $331 | $28 |
| Pathology examination of tissue using a microscope, limited examination | 78 | $319 | $4 |
| Preparation of tissue for examination by removing any calcium present | 26 | $298 | $11 |
Medicaid work
$2,259 in 2024
Medicaid paid $2,259 for 13 billed services this clinician did in 2024, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| TISSUE EXAM BY PATHOLOGIST | 13 | $2,259 |
| 2024 | 13 | 1 | 12 | $2,259 |
| 2023 | 17,039 | 44 | 393 | $4,625 |
| 2022 | 18,827 | 43 | 341 | $5,252 |
| 2021 | 48 | 1 | 17 | $699 |
| 2020 | 33 | 1 | 20 | $620 |
| 2019 | 48 | 1 | 18 | $442 |
| 2018 | 25 | 1 | 13 | $412 |
See the largest Medicaid services in earlier years
2023
| TISSUE EXAM BY PATHOLOGIST | 15 | $872 |
| COMPREHENSIVE METABOLIC PANEL | 2,642 | $827 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 3,125 | $624 |
| Troponin, quantitative | 833 | $216 |
| ASSAY OF LIPASE | 880 | $198 |
| Natriuretic peptide (heart and blood vessel protein) level | 302 | $192 |
| Thyroid stimulating hormone (TSH) | 297 | $182 |
| Culture, bacterial; quantitative colony count, urine | 508 | $158 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy | 1,131 | $143 |
| URINE PREGNANCY TEST | 58 | $134 |
| Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique | 131 | $103 |
| BLOOD CULTURE FOR BACTERIA | 277 | $76 |
2022
| Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; by instrument chemistry analyzers (eg, utilizing immunoassay [eg, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), chromatography (eg, GC, HPLC), and mass spectrometry either with or without chromatography, (eg, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) includes sample validation when performed, per date of service | 289 | $724 |
| NFCT DS 22 TRGT SARS-COV-2 | 129 | $667 |
| COMPREHENSIVE METABOLIC PANEL | 2,781 | $630 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 3,180 | $541 |
| Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), amplified probe technique | 409 | $460 |
| Thyroid stimulating hormone (TSH) | 402 | $170 |
| Alcohol (ethanol); any specimen except urine and breath, immunoassay (eg, IA, EIA, ELISA, RIA, EMIT, FPIA) and enzymatic methods (eg, alcohol dehydrogenase) | 298 | $166 |
| Measurement of acetaminophen | 211 | $164 |
| Troponin, quantitative | 760 | $135 |
| ASSAY OF LIPASE | 843 | $134 |
| Measurement of salicylate | 197 | $134 |
| Natriuretic peptide (heart and blood vessel protein) level | 321 | $122 |
2021
| TISSUE EXAM BY PATHOLOGIST | 48 | $699 |
2020
| TISSUE EXAM BY PATHOLOGIST | 33 | $620 |
2019
| TISSUE EXAM BY PATHOLOGIST | 48 | $442 |
2018
| TISSUE EXAM BY PATHOLOGIST | 25 | $412 |
Money from drug and device companies
$37 in 2020
| 2020 | 2 | 2 | None | $37 |
| 2019 | 8 | 11 | None | $260 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Bayer HealthCare Pharmaceuticals | Nubeqa | $22 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Imfinzi | $15 | 1 payment
|
See all 2 published payments
| Bayer HealthCare Pharmaceuticals | Meals · 2020-02-12 | Nubeqa | $22 |
| AstraZeneca Pharmaceuticals LP | Meals · 2020-01-15 | Imfinzi | $15 |
See earlier years (2019)
2019: $260
| Janssen Biotech | Erleada | $52 | 2 payments
|
| Foundation Medicine | Foundationone | $43 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $37 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $36 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | None | $30 | 1 payment
|
| Rigel Pharmaceuticals | Tavalisse | $25 | 1 payment
|
| Incyte | Jakafi | $22 | 1 payment
|
| Celgene | Revlimid | $15 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 90.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1023206810
- Licence
- CA A96558California A96558: Current · expires 2027-11-30
- Trained
- Saint Louis University School of Medicine, 2005 · 21 years ago
- Group
- Stanford Health Care
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207ZP0102X (207ZP0102X); Federal specialty code 207ZC0006X (207ZC0006X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-10-05
- NPI last updated
- 2024-03-13
- NPI record certified
- 2024-03-13
This is when the NPI record was last certified, not a medical board exam.